Shots:

• Inotrem enters into a global licensing agreement with Roche Diagnostics to commercialize mechanism-based CDx test utilizing a soluble plasma protein (sTREM-1)
• The collaboration leads towards the enhancement of Inotrem’s approach targeting TREM-1 pathway and allows it to focus on the development of a nangibotide-based septic shock treatment
• LR12 (nangibotide) is the first-in-class TREM-1 inhibitor with the potential to treat septic shock and MI. Inotrem has initiated its P-IIb ASTONISH study with a focus to demonstrate the efficacy of nangibotide- and bring clinically relevant proof of clinical activity in patients with septic shock

Click here ­to­ read full press release/ article 

Ref: Inotrem | Image: Roche